Managed by Brandon Capital, Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries originating from member research organisations, providing both capital and expertise to guide the successful development of new therapies.
Brandon BioCatalyst is a unique collaboration of investors, CSL, government and more than 50 leading medical research institutes and hospitals united by a single purpose: generating cutting edge, next generation medical therapies and technologies to improve health and save lives.
50+ Medical research institutes and hospitals
NSW Government Health
Government of South Australia
Western Australian Government
Ministry of Business, Innovation & Employment (MBIE) NZ
Murdoch Childrens Research Institute is the preeminent child health research institute in Australia, and is recognised globally for its child health discoveries.View
Our vision is to perform world-class medical research that focuses on the molecular basis of health and disease. The specific areas of our research include cancer, molecular bioscience, metabolic and musculoskeletal medicine, infection and immunity.View
Alfred Health is a leader in health care delivery, improvement, research and education. It strives to achieve best possible health outcomes for patients and the community by integrating clinical practice with research and education.View
Brandon Capital manages Brandon BioCatalyst, providing seed and venture capital investment to support the development and international growth of Australian and New Zealand life science companies.Brandon Capital website
Through the internship it was fantastic to understand what Brandon are looking for in the projects they fund. The learnings from the internship program will be applied to the new projects we develop, both in reviewing the opportunity and developing a solid business plan that will increase the commercial success.
The internship was a valuable experience that filled a critical gap in my knowledge of how early-stage life science technologies are commercialised. Up to this point, my experience was from a technology development perspective, and I did not have a full understanding of what investors were seeking in potential investments. The internship experience is immeasurable and will pay dividends well into the future.
The internship was an excellent learning and development opportunity. I greatly improved my understanding of the venture capital financing model and elements such as valuation, due diligence, market analysis and drug development. The MRCF internship program also enabled me to expand my national commercialisation networks and work alongside experienced biotech investors.